

DAFTAR PUSTAKA

Abdou HM. *Dissolution, Bioavailability, and Bioequivalence*. Pennsylvania: Mark Publishing Company Easton; 1989.

Aitipamula S, Banerjee R, Bansal AK, Biradha K, Cheney ML. Polymorphs, Salts, and Cocrystals: What's in a Name? *Crystal Growth Design*. 2012;12:2147-52.

Al-Thani RF, Al-Meri HA. *Study of Some Lichens of Qatar (Short Communication)*. *Atl. J. Biol.* 2011;1(3): 41-46.

Almarsson Ö, Peterson ML, Zaworotko M. *The A to Z of Pharmaceutical cocrystals: a decade of fast-moving new science and patents*. *Pharm Pat Anal.* 2012;1:313-27.

Ansel, HC. *Pengantar Bentuk Sediaan Farmasi* (Ed. 4). (Farida Ibrahim, penerjemah). Depok: UI Press; 1989.

Backor M, Hudak J, Ziegler W & Backrovora M. The Influence of Lichen Metabolites (Vulpinic Acid Ang (+) Usnic Acid) on The Growth of The Lichen Photobiont *Trebouxia Irregularis*. *Lichenologist*. 1998;6 (30): 577-582.

Bagde SA, Upadhye KP, Gauri RD, & Suparna SB. Formulation and Evaluation of Co-Crystals of Poorly Water Soluble Drug. *International Journal of Pharmaceutical Sciences and Research*. 2016;12 (3): 4988-4997.

Banakar UV. *Pharmaceutical Dissolution Testing*. New York: Marcel Dekker Inc; 1991.

Basajovu S, Bostrom D, Velaga SP. Indomethacin-Saccharin Cocrystal: Design, Synthesis and Preliminary Pharmaceutical Characterization. *Pharmaceutical Research*. 2008;25(3):530-540.

Billmeyer, Fred A. *Textbook of Polymer Science (3rd ed.)*. New York: John Wiley & Sons, Inc; 1984.

Brittain HG. *Analytical Profiles of Drugs Substances and Excipients (Volume 26)*. California: Academic Press; 1999.

Cardarelli M, Serino G, Campanella L, Ercole P, Nardone FDC, Alesiani O, Rossiello F. Antimitotic effects of usnic acid on different biological systems. *Cell. Mol. Life Sci.* 1997;53:667-672.

Cocchietto M, Skert N, Nimis PL. *A Review on Usnic Acid, An Interesting Natural Compound*. *Naturwissenschaften*. 2002;89:137-149.

Costayz RM, Ribeir AJ, Alvesz NP, Santosy SC, Nascimento ECP, Gonc, Alves NH, Silva NK, Honda dan Santos-Magalhaes. In Vitro and In Vivo Properties of Usnic Acid Encapsulated into PLGA-Microspheres. *Journal of Microencapsulation*. 2003;21(44):371–384.

Cruz-Cabeza AJ. Acid Base Crystalline Complex and The pKa Rule. *Crystal Engineering Communication*. 2012;14:6362-6365.

Davis RE, Lorimer KA, Wilkowski MA, Rivers JH. Studies of relationship in cocrystal systems. *ACA Transactions* 2004; 39: 41-61.

Departemen Kesehatan RI. *Farmakope Indonesia Edisi Keempat*. Jakarta: Departemen Kesehatan RI; 1995.

Fanun M. *Colloids in Drug Delivery*. USA: CRC Press; 2010.

Friscic T, Scott LC, Syed AA, William J. The Role of Solvent in Mechanochemical and Sonochemical Cocrystal Formation: A *Solubility-Based Approach for Predicting Cocrystallisation Outcome*. RSC Publishing; 2008.

Grohgan, H., Lobmann, K., Priemel, P., Jensen, K.T., Graeser, K., Strachan, C., Rades, T. Amorphous drugs and dosage forms. *J. Drug Deliv. Sci. Technol*. 2013;23:403–408.

Haeria, Asia M, Muh F. Karakterisasi Kokristal Parasetamol-Asam Suksinat melalui Metode *Solvent Drop Grinding*. [Skripsi]. Makassar: Universitas Islam Negeri Alauddin Makassar; 2015.

Harmita. *Buku Ajar Analisis Fisikokimia*. Depok: Departemen Farmasi FMIPA Universitas Indonesia. 2006: 40-59.

Hawranik DJ, Anderson KS, Simmonds R, Sorensen JL. *The Chemoenzymatic Synthesis of Usnic Acid*. *Bioorg. Med. Chem. Lett*. 2009;19:2383–2385

Ingoldsdottir K. Usnic Acid. *Phytochemistry*. 2002;61 (7): 729–736.

Jin JQ, Rao Y, Bian X, Zeng A, Yang G. *Solubility of (+)-Usnic Acid in Water, Ethanol, Acetone, Ethyl Acetate and n-Hexane*. New York; 2013.

Kalepu S, Nekkantib V. *Insoluble Drug Delivery Strategies: Review of Recent Advances and Business Prospects*. Department of Pharmaceutical Technology: India; 2015.

Lachman L, Herbert AL, Joseph LK. *The theory and practice of industrial pharmacy* (2nd ed). Philadelphia: Lea & Febiger. 1970;1(31):118.

Loftsson T, Brewster ME, Masson M. Role of Cyclodextrins in Improving Oral Drug Delivery. *Technology Tools Article*. Iceland: Faculty of Pharmacy University of Iceland; 2004.

Martin AJS, dan Cammarata A. *Physical Pharmacy (1st and 2nd ed)*. Philadelphia: Lea & Febiger. 1990; 846:559-637.

Miroshnyk I., Mirza S. and Sandler N., Expt. Opin. *Drug Deliv*. 2009;6:333.

Nisak RK. Pengaruh Pembentukan Kokristal Asam Usnat - N-Methyl-D-glucamine dengan Metode *Solvent Drop Grinding* terhadap Kelarutan dan Profil Disolusi. Fakultas Farmasi Universitas Andalas: Padang; 2017.

O'Neil. The Merck Index 13th edition. New Jersey. Merk & Co. Inc; 2001.

Prasad RV, Rakesh MG, Jyotsna RM, Mangesh ST, Sapkale P, Mayur PK. Pharmaceutical Cocrystallization : A Review. *International Journal of Pharmaceutical Chemistry Sciences*. 2012;3(1): 725–36.

Qiao N, Li M, Schlindwein W, Malek N, Davies N, Trappitt G. Pharmaceutical Cocrystals: An Overview. *International Journal of Pharmaceutics*. 2011;419: 1-11.

Qu C, Zhang L, Du X, Zhang X, Zheng J, Zhao Y, Tu P. Preparation and Evaluation of Wet-Milled Usnic Acid Nanocrystal Suspension for Better Bioaffinity. *Drug Development and Industrial Pharmacy Article*. Beijing University; 2017.

Rahmasari A. Karakterisasi Produk Pengeringan Beku Ketoprofen-N-Metilglukamin. [Skripsi]. Surabaya: Universitas Airlangga; 2006.

Rowe RC, Sheskey PJ, Quinn ME. *Handbook of Pharmaceutical Excipients*. Washington: American Pharmacist Association; 2009.

Sangster J. LogKow Databank. Canada: Sangster Res. Lab; 1993.

Sanjay AN, Manohar SD, Bhanudas SR. Pharmaceutical Cocrystallization: A Review. Department of Pharmaceutics, KCT'S RGS College of Pharmacy: India; 2014.

Sathigari S, Chadha G, Lee YHP, Wright N, Parsons DL, Rangari VK, Fasina O, & Babu RJ. Physicochemical Characterization of Evavirenz-Cyclodextrin Inclusion Complex. *AAPS Pharmaceutical Science Technology*. 2009;10(1) : 81-87.

Schultheiss N, Ann N. *Pharmaceutical Cocrystal and Their Physicochemical Properties*, Crystal Growth & Design. 2009; 9: 2951-2965.

Shargel L, & Yu ABC. *Applied Biopharmaceutics And Pharmacokinetics* (2th edition). New York: Appleton & Lange; 1988.

Stuart, Barbara. *Infrared Spectroscopy: Fundamental and Application*. New York: Jhon Wiley & Sons, Ltd; 2004.

Su ZQ, Mo ZZ, Liao JB, Feng XX, Liang YZ, Zhang X, Liu YH, Chen XY, Chen ZW, Su ZR, Lai XP. Usnic Acid protects LPS-induced acute lung injury in mice through attenuating inflammatory responses and oxidative stress. *International Immunopharmacology Journal*. 2014;22: 371-378.

Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez- Hornedo N. *Pharmaceutical Cocrystals and Poorly Soluble Drugs*. *Int J Pharm*. 2013;453:101(25):54.

Thipparaboina, R., Kumar, D., Chavan, R.B. & Shastri, N.R. Multidrug Co-Crystals: Towards the Development of Effective Therapeutic Hybrids. *Drug Discovery Today*. 2016;21(3) : 481-490.

Trask AV, Motherwell WDS dan Jones W. Pharmaceutical Cocrystals : An Emergin Approach To Physical Property Enhancement. *Mrs Bulletin*. 2006;31, 976-879.

Utami RD. Pembentukan Kokristal Asam Usnat dan 4- Aminopiridin dengan Metode *Solvent Drop Grinding*. Fakultas Farmasi Universitas Andalas: Padang; 2017.

Vijayakumar CS, Viswanathan S, Kannappa, Reddy M, Parvathavarthini S, Kundu AB, Sukumar E. Antiinflammatory activity of (p)-usnic acid. *Fitoterapia*. 2000;71: 564–566.

Vesna N, Mihajlo, Ljubisa N, Goran N, Snezana IS, Mirjana P, Sasa Z, & Tatjana K. *Inclusion Complexes With Cyclodextrin and Usnic Acid*. *J. Incl. Phenom Macrocycl Chem*. 2012;76:173-182.

Wouters J, Luc Q. *Pharmaceutical Salts and Co-crystals*. RSC Publishing; 2012.

Zaini, E., A.Halim, S.N. Soewandhi dan D. Setiawan. Peningkatan Laju Pelarutan Trimetoprim melalui Metode Ko-Kristalisasi Dengan Nikotinamida. *Jurnal Farmasi Indonesia*. 2011;5(4) 205 -212.